Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Center for Breakthrough Medicines Appoints Joerg Ahlgrimm as CEO | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

Center for Breakthrough Medicines Appoints Joerg Ahlgrimm as CEO

Mr. Ahlgrimm joined CBM in September 2020 as chief operating officer.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

The Center for Breakthrough Medicines (CBM), an end-to-end advanced therapy contract development and manufacturing organization (CDMO), has appointed Joerg Ahlgrimm as CEO. CBM provides pre-clinical through commercial manufacturing including process development, plasmid DNA, viral vectors, cell banking, cell processing and supporting testing capabilities.
 
Mr. Ahlgrimm brings over 20 years of expertise in the areas of operations and supply chain management and has served in multi-billion-dollar companies operating in biotech, vaccines, pharmaceutical and medical device markets. His focus is on superior customer service, strategy development, execution management, productivity improvement, organizational development, team building and leadership. 
 
Prior to joining CBM, Mr. Ahlgrimm was head of global operations for pharma, biotech and nutrition at Lonza, where he was responsible for 37 sites on four continents and over 8,000 employees. Before Lonza, Mr. Ahlgrimm was head of global manufacturing for Baxter Healthcare’s bioscience division, Baxalta Inc. In this senior leadership role, he led Baxalta’s internal and external manufacturing network and created an impressive track record in customer service, growth and operational efficiency.
 
“We are thrilled about Joerg’s appointment to CEO,” said Audrey Greenberg, co-founder, CBM. “Joerg’s ‘team player’ mentality, ability to roll up his sleeves, and deep industry relationships will be a game changer for CBM and the advanced therapies industry. Joerg has a proven ability to execute on large-scale projects. Joerg’s extraordinary achievements for the pharma, biotech, and CDMO industries combined with his incredible leadership, makes him the ideal choice to head our executive management team and build CBM into an advanced therapy powerhouse.”
 
Mr. Ahlgrimm joined CBM in September 2020 as chief operating officer. 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters